利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

57 条记录 (耗时 0.042 秒)

    Angiotensin II receptor antagonists
    41.
    发明授权
    Angiotensin II receptor antagonists 有权
    血管紧张素II受体拮抗剂

    公开(公告)号：US07880014B2

    公开(公告)日：2011-02-01

    申请号：US12000247

    申请日：2007-12-11

    申请人： Iyassu K. Sebhat ,  Michael Man-chu Lo ,  Ravi P. Nargund ,  Amjad Ali ,  Chris Franklin ,  Nicoletta Almirante ,  Laura Storoni ,  Silvia Stefanini

    发明人： Iyassu K. Sebhat ,  Michael Man-chu Lo ,  Ravi P. Nargund ,  Amjad Ali ,  Chris Franklin ,  Nicoletta Almirante ,  Laura Storoni ,  Silvia Stefanini

    IPC分类号： C07D257/00 ,  C07D403/00

    CPC分类号： C07D403/10

    摘要： A compound having the structure wherein R is an angiotensin receptor antagonist active group, Y is -Y1-Y2-Y3-Y4-Y5-; Y1 is C(R1R2); R1 is selected from the group consisting of hydrogen and C1-4 alkyl; R2 is selected from the group consisting of hydrogen, C1-4 alkyl, and —OC(O)C1-4 alkyl; Y2 is O or CH2; Y3 is C(O) or CH2; Y4 is O or CH2; Y5 is —(CH2)1-2—(X)0-1—(CH2)0-1— or is absent; X is —O— or —CR3R4—; and R3 and R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.

    摘要翻译： 具有结构的化合物，其中R是血管紧张素受体拮抗剂活性基团，Y是-Y1-Y2-Y3-Y4-Y5-; Y1是C（R1R2）; R 1选自氢和C 1-4烷基; R 2选自氢，C 1-4烷基和-OC（O）C 1-4烷基; Y2是O或CH2; Y 3是C（O）或CH 2; Y4是O或CH2; Y 5是 - （CH 2）1-2 - （X）0-1 - （CH 2）0-1-或不存在; X是-O-或-CR 3 R 4 - ; 并且R 3和R 4独立地选自氢和C 1 -C 4烷基; 或其药学上可接受的盐或水合物，其可用于治疗高血压。

    ANGIOTENSIN II RECEPTOR ANTAGONISTS
    44.
    发明申请
    ANGIOTENSIN II RECEPTOR ANTAGONISTS 审中-公开
    ANGIOTENSIN II受体拮抗剂

    公开(公告)号：US20100152259A1

    公开(公告)日：2010-06-17

    申请号：US12516482

    申请日：2007-12-11

    申请人： Iyassu K. Sebhat ,  Michael Man-chu Lo ,  Ravi P. Nargund ,  Amjad Ali ,  Chris Franklin ,  Nicoletta Almirante ,  Laura Storoni ,  Silvia Stefanini

    发明人： Iyassu K. Sebhat ,  Michael Man-chu Lo ,  Ravi P. Nargund ,  Amjad Ali ,  Chris Franklin ,  Nicoletta Almirante ,  Laura Storoni ,  Silvia Stefanini

    IPC分类号： C07D403/10 ,  A61K31/4184 ,  A61P9/12

    CPC分类号： C07D403/10

    摘要： A compound having the structure (Formula I), wherein R an angiotensin receptor antagonist active group, Y is Y1—Y2—Y3—Y4—Y5. Y1 is C(R1R2); R1 is selected from the group consisting of hydrogen and C1-4 alkyl; R2 is selected from the group consisting of hydrogen, C1-4 alkyl, and -0C(0)C1-4 alkyl; Y2 is O or CH2; Y3 is C(O) or CH2; Y4 is O or CH2; Y5 is —(CH2)1-2—(X)0-1—CH2)0-1— or is absent; X is —O— or —CR3R4—; and R3 and R4 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; or a pharmaceutically acceptable salt or hydrate thereof, which is useful for treating hypertension.

    摘要翻译： 具有结构（式I）的化合物，其中R为血管紧张素受体拮抗剂活性基团，Y为Y1-Y2-Y3-Y4-Y5。 Y1是C（R1R2）; R 1选自氢和C 1-4烷基; R 2选自氢，C 1-4烷基和-C（O）C 1-4烷基; Y2是O或CH2; Y 3是C（O）或CH 2; Y4是O或CH2; Y 5是 - （CH 2）1-2 - （X）0-1-CH 2）0-1-或不存在; X是-O-或-CR 3 R 4 - ; 并且R 3和R 4独立地选自氢和C 1 -C 4烷基; 或其药学上可接受的盐或水合物，其可用于治疗高血压。

    Acylated Spiropiperidine Derivatives as Melanocortin-4 Receptor Modulators
    46.
    发明申请
    Acylated Spiropiperidine Derivatives as Melanocortin-4 Receptor Modulators 有权
    酰基化Spiropiperidine衍生物作为黑皮质素-4受体调节剂

    公开(公告)号：US20090170863A1

    公开(公告)日：2009-07-02

    申请号：US11992262

    申请日：2006-09-25

    申请人： Tianying Jian ,  Jian Liu ,  Ravi P. Nargund

    发明人： Tianying Jian ,  Jian Liu ,  Ravi P. Nargund

    IPC分类号： A61K31/438 ,  A61K31/501 ,  A61K31/497 ,  A61K31/506 ,  C07D491/147 ,  C07D471/10

    CPC分类号： C07D471/10

    摘要： Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

    摘要翻译： 某些新型N-酰化螺哌啶衍生物是人类黑皮质素受体的配体，特别是人黑素皮质素-4受体（MC-4R）的选择性配体。 因此，它们可用于治疗，控制或预防对调节MC-4R的疾病和病症，例如肥胖，糖尿病，尼古丁成瘾，酒精中毒，性功能障碍，包括勃起功能障碍和女性性功能障碍。